Answers are grounded in this paper and cite their sources.
Clinical validation reveals plasma p-217tau levels indicate neurological disease severity, suggesting diagnostic potential.
ALS and iNPH are two major pitfalls for the clinical application of plasma p-217tau as a biomarker of AD. Lower motor neuron injury in ALS and cognitive dysfunction in iNPH were both found to be associated with elevated plasma p-217tau levels.
No takes yet. Share an insight, caveat, or question.
Kawarabayashi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: